Drug Trial Radar · NCT04724980
Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis
Last checked: Nov 19, 2026Latest source record: Jun 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
38
Actual
Start
Mar 16, 2021
Primary completion
Jun 5, 2024
Study completion Jun 5, 2026
Sponsor
- Lead sponsor
- Precigen, IncIndustry
- Sponsor type
- Industry
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Jan 26, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2 study in patients with a Recurrent Respiratory Papillomatosis (RRP) disease burden that requires repeated surgical procedures for management. RRP is a rare disease caused by the human papillomavirus (HPV). Participants with a pathologically confirmed diagnosis of papilloma and a clinical diagnosis of RRP will be screened for this protocol.
Conditions
- Recurrent Respiratory Papillomatosis
- Papillomavirus Infections
- Papillomaviridae
Interventions
PRGN-2012 - Phase I; Dose Level 1Drug
In Phase 1, dose level 1 of the clinical trial, PRGN-2012 is administered at 1 × 10\^11 particle units as adjuvant therapy prior to standard debulking surgery.
PRGN-2012 - Phase I; Dose Level 2Drug
In Phase 1, dose level 2 of the clinical trial, PRGN-2012 is administered at 5 × 10\^11 particle units as adjuvant therapy prior to standard debulking surgery.
PRGN-2012 - Phase II; Dose Level 2Drug
The Phase 2 portion is designed as a dose expansion study where patients are treated at the RP2D of 5 x 10\^11 PU.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determine the percentage of subjects with a complete response following treatment with PRGN-2012Time frame: 1 year
- Determine the incidence of dose limiting toxicities to evaluate safety and identify RP2D of PRGN-2012Time frame: 28 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Institutes of Health Clinical Center
Bethesda, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.